Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (ATHE)

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alterity Therapeutics Limited logo

Alterity Therapeutics Limited

NASDAQ:ATHEHealthcare
+0.00%$1.96
CLOSED
AH$1.96+0.00%vs close
Mkt Cap$37.42M
EV-
Float16.12M
O/S19.09M
VOL13K sh
$ Vol$26K
RVOL0.06×
Inst Own2.0%
SI0.1%
Net Cash/Sh-
Dilution
Alterity Therapeutics Limited logoNASDAQ:ATHEClosed$1.96+0.00%